A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation

作者: Lutz Eric , Charles J Yeo , Keith D Lillemoe , Barbara Biedrzycki , Barry Kobrin

DOI: 10.1097/SLA.0B013E3181FD271C

关键词: Survival rateCancer researchGVAXPancreatic cancerMedicineAdenocarcinomaT cellPancreatic diseaseImmunologyImmunotherapyPancreatic tumor

摘要: Pancreatic cancer remains the fourth leading cause of related death in United States.1 Surgical resection provides only possibility cure. However, historical 5-year survival postresection approximately 15% to 20%, with 1 and 2-year 63% 42% respectively.2 A standard adjuvant treatment approach for patients resected disease has not yet been determined.2–11 We developed irradiated GM-CSF transfected allogeneic whole cell tumor lines pancreas ductal adenocarcinoma immunotherapy.12 We previously reported that this immunotherapy administered intradermally sequence chemoradiotherapy pancreatic induced posttreatment delayed type hypersensitivity (DTH) responses autologous cells 3 participants receiving × 108 2 5 vaccine cells. The DTH responders are who remain disease-free at 10+ years. Importantly, immunized lymphocytes from DTH-responders were used screen a number differentially expressed genes cancer. All demonstrated postimmunotherapy T response mesothelin, glycosyl-phosphatidylinositol (GPI)-linked surface protein likely serves as an adhesion molecule promotes metastases.13–16 We now report results single institution 60 patient phase II study testing highest dose secreting found be safe bioactive I testing. This was designed estimate overall rates prevalence mesothelin-specific associated treatment.

参考文章(22)
Elizabeth M. Jaffee, Ralph H. Hruban, Tim F. Greten, Mieke Schutte, Charles J. Yeo, Constance A. Griffin, Adam J. Adler, Laura A. Morsberger, Matthew Thomas, Jeanette Gossett, Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. The cancer journal from Scientific American. ,vol. 4, pp. 194- 203 ,(1998)
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
T SOHN, C YEO, J CAMERON, L KONIARIS, S KAUSHAL, R ABRAMS, P SAUTER, J COLEMAN, R HRUBAN, K LILLEMOE, Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. Journal of Gastrointestinal Surgery. ,vol. 4, pp. 567- 579 ,(2000) , 10.1016/S1091-255X(00)80105-5
Min Li, Uddalak Bharadwaj, Rongxin Zhang, Sheng Zhang, Hong Mu, William E. Fisher, F. Charles Brunicardi, Changyi Chen, Qizhi Yao, Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Molecular Cancer Therapeutics. ,vol. 7, pp. 286- 296 ,(2008) , 10.1158/1535-7163.MCT-07-0483
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M. J. Thun, Cancer statistics, 2008. CA: A Cancer Journal for Clinicians. ,vol. 58, pp. 71- 96 ,(2008) , 10.3322/CA.2007.0010
John P. Neoptolemos, Deborah D. Stocken, Helmut Friess, Claudio Bassi, Janet A. Dunn, Helen Hickey, Hans Beger, Laureano Fernandez-Cruz, Christos Dervenis, François Lacaine, Massimo Falconi, Paolo Pederzoli, Akos Pap, David Spooner, David J. Kerr, Markus W. Büchler, A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer New England Journal of Medicine. ,vol. 350, pp. 1200- 1210 ,(2004) , 10.1056/NEJMOA032295
Dengfeng Cao, Anirban Maitra, Jorge-Albores Saavedra, David S Klimstra, N Volkan Adsay, Ralph H Hruban, Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Modern Pathology. ,vol. 18, pp. 752- 761 ,(2005) , 10.1038/MODPATHOL.3800363
D D Stocken, , M W Büchler, C Dervenis, C Bassi, H Jeekel, J H G Klinkenbijl, K E Bakkevold, T Takada, H Amano, J P Neoptolemos, Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer British Journal of Cancer. ,vol. 92, pp. 1372- 1381 ,(2005) , 10.1038/SJ.BJC.6602513
William F. Regine, Kathryn A. Winter, Ross A. Abrams, Howard Safran, John P. Hoffman, Andre Konski, Al B. Benson, John S. Macdonald, Mahesh R. Kudrimoti, Mitchel L. Fromm, Michael G. Haddock, Paul Schaefer, Christopher G. Willett, Tyvin A. Rich, Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. ,vol. 299, pp. 1019- 1026 ,(2008) , 10.1001/JAMA.299.9.1019